## Analysis of Nephrotic Syndrome Complications and Management ### The Incorrect Statement (Option D) **Key Point:** The statement that loop diuretics are preferred over thiazide diuretics because they "remain effective even with reduced GFR" is **misleading and partially false**. While loop diuretics are indeed more potent and are the first-line diuretics in nephrotic syndrome, the stated reason is not entirely accurate. Thiazide diuretics act on the distal convoluted tubule and can retain some efficacy even at reduced GFR levels; in fact, thiazides are frequently **combined** with loop diuretics to overcome loop diuretic resistance in nephrotic syndrome (a well-recognized clinical strategy). The blanket claim that loop diuretics are preferred *because* thiazides are ineffective with reduced GFR oversimplifies the clinical reality and is the least accurate statement among the options. Furthermore, the primary reason loop diuretics are preferred in nephrotic syndrome is their greater potency and ability to overcome the blunted tubular response caused by hypoalbuminemia (reduced free drug delivery), not simply GFR-related thiazide failure. Thiazide + loop diuretic combination is a standard approach for diuretic resistance in nephrotic syndrome (Harrison's Principles of Internal Medicine, 21st ed.). ### Why the Other Options Are Correct #### Option A: Hypercoagulability Mechanism **High-Yield:** Nephrotic syndrome causes a hypercoagulable state through: - Urinary loss of anticoagulant proteins (protein C, protein S, antithrombin III, plasminogen) - Increased hepatic synthesis of procoagulant factors (fibrinogen, factors V, VII, VIII, X) - Increased platelet aggregability - Hemoconcentration from volume depletion This is a well-established mechanism and a classic NEET PG fact (Harrison's, Robbins). #### Option B: ACE Inhibitors in Membranous Nephropathy **Clinical Pearl:** ACE inhibitors and ARBs DO reduce proteinuria in membranous nephropathy through mechanisms that are **partly independent of systemic blood pressure reduction**, including reduction of intraglomerular pressure via efferent arteriolar dilation and direct effects on glomerular permeability. This antiproteinuric effect is well-supported in standard texts (KD Tripathi Pharmacology; Harrison's) and is a cornerstone of conservative management in membranous nephropathy. This statement is TRUE. #### Option C: Hyperlipidemia Pathophysiology **Clinical Pearl:** The mechanism is: 1. Hypoalbuminemia → loss of oncotic pressure feedback 2. Liver responds by increasing synthesis of ALL plasma proteins, including lipoproteins (VLDL, LDL) 3. Urinary loss of HDL and apolipoprotein A-I 4. Net result: elevated cholesterol and triglycerides This is a correct and well-established mechanism (Robbins Pathologic Basis of Disease, 10th ed.). ### Summary Table: Nephrotic Syndrome Pathophysiology | Feature | Mechanism | Clinical Consequence | |---------|-----------|---------------------| | Proteinuria | Glomerular permeability ↑ | Protein loss >3.5 g/day | | Hypoalbuminemia | Urinary loss > hepatic synthesis | Edema, ↓ oncotic pressure | | Hypercoagulability | Loss of anticoagulants + ↑ synthesis | VTE risk (especially MN) | | Hyperlipidemia | ↑ Hepatic synthesis (feedback loss) | Atherosclerosis risk | | Edema | ↓ Plasma oncotic pressure | Peripheral, periorbital, ascites | --- **Clinical Pearl:** Membranous nephropathy carries the highest thrombotic risk among nephrotic causes (up to 40% develop VTE). Anticoagulation prophylaxis is considered if serum albumin <2 g/dL or proteinuria >10 g/day. For diuretic-resistant edema in nephrotic syndrome, combining a loop diuretic with a thiazide (metolazone) is a standard clinical strategy — contradicting the premise of Option D.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.